Industry veteran Fred Hassan joins the board of Norstella
Norstella, a leader in helping patients gain access to life-saving therapies by navigating the complexities at each step of the drug development life cycle, is pleased to announce that Fred Hassan has joined its board of directors. Hassan brings a wealth of experience and expertise in healthcare, having served as CEO of several major pharmaceutical companies and as a board member of numerous healthcare organizations. He has held senior leadership roles at some of the world's most prominent organizations, including Schering-Plough, Pharmacia Corporation, and Bausch & Lomb.
Press Releases | Apr. 04, 2023
TriNetX and Clinerion unite as TriNetX and Norstella announce strategic partnership
Cambridge, MA, April 4, 2023 — TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of novel therapies, and Norstella, the leading pharmaceuticals solutions provider, today announced a multi-faceted strategic partnership. As part of this exciting partnership, TriNetX will acquire Norstella’s Clinerion Ltd. subsidiary, expanding the growth of the world’s leading research network for real world data (RWD).
Press Releases | Mar. 30, 2023
Citeline launches TrialScope intelligence, meeting the growing complexities of clinical trial disclosure
Clinical trial disclosure compliance is challenging, whether a sponsor is registering five trials or 500 trials. Compounding the complexity is the fact that no global standards exist for disclosure. With ever-changing global regulations, new requirements on the rise and the threat of monetary penalties, study sponsors are feeling the pressure to maintain compliance, minimize risk and safeguard their brand reputation.
In the News | Mar. 07, 2023
How robust data technology is transforming the design and execution of viable clinical trials
While incorporating real-world data (RWD) and real-world evidence (RWE) across the drug development lifecycle is getting a lot of attention, the application of such insights gleaned from rigorous analysis to the design and execution of clinical trials has yet to be widely adopted, despite its potential to address some of these persistent challenges.
In the News | Jan. 08, 2023
What do you view as the most disruptive or transformational technology or development on the horizon?
Norstella CEO, Mike Gallup, weighs in on the most disruptive / transformational technology on the horizon in a recent pharma’s almanac piece. “As regulators and payers look for new information to guide their decision-making, real-world data and evidence are poised to play a transformative role in not only getting drugs to market quickly, but also ensuring that patients can access them.”
Press Releases | Dec. 09, 2022
Exclusive AIS Health data outlines 2021 compensation for health insurer CEOs
Washington, DC, Dec. 9, 2022 — In AIS Health’s annual roundup of health insurer executive compensation data, four newly public startup insurers stand out. But the stock awards that are largely driving their eye-popping total compensation figures — such as Clover Health Investments Corp. CEO Vivek Garipalli’s $390 million or Bright Health Group, Inc. CEO Mike Mikan’s $181 million — are based in part on the firms’ initial public offering (IPO) stock valuations, which were many times higher than what their shares are now worth.
In the News | Nov. 14, 2022
Industry leaders offer reflections on 2022 and predictions for 2023
The COVID-19 pandemic has continued to evolve, forcing companies to adapt to a constantly changing landscape filled with fluid consumer expectations. Meanwhile, several other key healthcare-related trends have bubbled to the surface over that period.
In the News | Nov. 14, 2022
What can we expect in pharma in 2023?
Drug pricing, CMS getting negotiating power for drug purchasing, vaccines, clinical trials, artificial intelligence, and Pharmacists becoming care givers. These are the highlights of 2022, what do the experts say we will see in 2023? We rounded up some experts and asked them just that. And join us for the next few weeks as we look at what we might see in 2023.
In the News | Nov. 14, 2022
The 2023 PharmaVoice crystal ball: peering into the future of life sciences
For the 2023 PharmaVoice Year in Preview, we zeroed in on six key trends: clinical trial diversity, disruptive tech, innovation, talent management, patient engagement and leading through uncertain times. Here, we’ve asked industry execs to look into their crystal balls and tell us about anything they see coming.
Press Releases | Nov. 01, 2022
Citeline and Norstella complete merger to form a $5 billion global pharmaceutical technology company
Nov. 1, 2022 – Norstella, a global leader with end-to-end solutions that smooth access to life-saving therapies for patients, has announced the completion of its merger with Citeline (formerly Pharma Intelligence), a leader in the clinical trial intelligence space.
At deal close, the $5 billion global company is now one of the world’s largest pharma intelligence solutions providers on the market, with more than 1,600 employees across the five brands that make up Norstella: Evaluate, MMIT, Panalgo, The Dedham Group, and now Citeline.
Press Releases | Jun. 28, 2022
Citeline and Norstella unite to offer life sciences clients a full suite of commercial and clinical solutions
June 28, 2022 – Norstella, an organization that helps life sciences companies navigate the complexities of the drug life cycle, and Citeline (formerly Pharma Intelligence)—a leading provider of specialist intelligence, data and software for clinical trials, drug development and regulatory compliance—have announced an agreement to merge the companies.
Press Releases | Jun. 23, 2022
MMIT announces winners of the Q1 2022 Patient Access Awards
June 23, 2022, Yardley, PA – Managed Markets Insight & Technology (MMIT)—the trusted go-to-market partner for overcoming barriers to patient access—has launched the inaugural Patient Access Awards to honor pharmaceutical manufacturers committed to improving patient access to life-saving therapies.